Mr. Quang Pham
Chairman and CEO
Mr. Pham is a biopharmaceutical entrepreneur with over 20 years of experience in founding, financing, and growing companies. Prior to founding Espero, he started Lathian Systems, an innovative company that provided online data and marketing services to pharmaceutical and biotech companies.
Mr. Jeff Cole
President and CFO
Mr. Cole has over 23 years of experience in finance, business development and commercial operations at public and privately held companies. This includes more than 15 years in the pharmaceutical industry holding various senior executive roles at companies such as Valeant Pharmaceuticals (NYSE: VRX), Solco Healthcare US, MarcasUSA, and Legacy Pharmaceuticals. His positions at Valeant included CFO North America, VP of Corporate Development, and General Manager of the US Specialty Division.
Mr. Wayne Yetter
Director and Senior Advisor
Mr. Yetter is a pharmaceutical industry veteran, board director and advisor. He has held leadership positions at global companies, including President and CEO of Novartis Pharmaceuticals and founding CEO of Astra-Merck (now AstraZeneca). He has also held senior roles at IMS Health, Odyssey Pharmaceuticals, and Verispan.
Mr. Stefan Roever
Mr. Roever has a broad entrepreneurial, software, and finance background. He is CEO and founder of Genia Technologies, a next generation DNA sequencing company based in Mountain View, CA. Genia was sold to Roche in June 2014 for $350 million. He’s also founder and Chairman of gBox, a video monetization and distribution platform.
Dr. Larry Hsu, Ph.D.
Dr. Hsu is currently Chairman & CEO of Lifemax Healthcare International Corporation and general partner at Hercules BioVenture Partners as well as Capital TEN II Fund. He co-founded Impax Pharmaceuticals, Inc., a drug-delivery technology-based pharmaceutical company with headquarters located in the San Francisco Bay Area.
Mr. Henrik Hesse
Currently Mr. Hesse serves as Executive Director at Pohl-Boskamp, managing Legal, Finance, and R&D. He also acts as an honorary judge for labor law with the court system in Germany. He started his career as an attorney with a law firm, prior to joining Pohl-Boskamp as General Counsel.
Dr. Peter G. Milner
Dr. Milner was a co-founder and Executive Chairman of Armetheon, Inc. He has been CEO of Heart Metabolics Limited UK (now HMBL) since 2011 and was also CEO of Heart Metabolics Limited Ireland from 2014 to 2015.
In 2007, Dr. Milner co-founded Optivia Biotechnology, a private company now recognized as a leader in the emerging field of transporter biology. He is also a co-founder and President & CEO of AshHill Pharmaceutical Investments, LLC. In 1997, Dr. Milner co-founded ARYx Therapeutics (NASDAQ:ARYX), where he served as CEO until 2005, and President from 2005 to 2010 with overall responsibility for R&D. In 1990, he co-founded CV Therapeutics (NASDAQ:CVTX), where as a member of senior management from 1992-1996, he in-licensed and co-invented several successful pharmaceuticals. CV Therapeutics was acquired by Gilead for $1.5B in cash in 2009.
In 2005, Dr. Milner was instrumental in restructuring his family pharmaceutical company ML Laboratories (MLB.LSE) and its subsequent merger to form Vectura (VEC.LSE), a profitable company and one of the world’s leading makers of inhaled products.
Prior to 1992, Dr. Milner was an assistant professor of medicine at Washington University in St. Louis. His research led to the discovery of pleiotrophin (PTN), a novel growth factor that regulates stem cell differentiation, organ development, and the epithelial mesenchymal transition (EMT). He was educated at the University of Liverpool, receiving his medical degree in 1980, before completing his postgraduate training at Johns Hopkins Hospital, The University of Virginia, and Washington University in St. Louis.
He is a Fellow of the American College of Cardiology (FACC), and a board-certified physician and cardiologist. He serves as adjunct clinical faculty at Stanford University School of Medicine and as a board member of the California Healthcare Institute (CHI).